Accessibility Menu
 
Arrow-Thin-Down
S&P 500
7,230.12
+0.3%
+21.11
Arrow-Thin-Down
DJI
49,499.27
-0.3%
-152.87
Arrow-Thin-Down
NASDAQ
25,114.44
+0.9%
+222.13
Arrow-Thin-Down
Bitcoin
$78,403.00
+0.2%
+$163.16
Arrow-Thin-Down
AAPL
$280.19
+3.3%
+$8.84
Arrow-Thin-Down
AMZN
$268.36
+1.2%
+$3.30
Arrow-Thin-Down
GOOG
$382.96
+0.3%
+$1.02
Arrow-Thin-Down
META
$608.57
-0.5%
-$3.34
Arrow-Thin-Down
MSFT
$414.40
+1.6%
+$6.62
Arrow-Thin-Down
NVDA
$198.61
-0.5%
-$0.96
Arrow-Thin-Down
TSLA
$390.97
+2.4%
+$9.34
Most Active StocksDaily Stock GainersDaily Stock Losers
PD-Rx Pharmaceuticals logo

PD-Rx Pharmaceuticals

(OTC) PDRX

Current Price$3.35
Market Cap$5.18M
Since IPO (1992)+265%
5 Year+23%
1 Year+21%
1 Month+1%

PD-Rx Pharmaceuticals Financials at a Glance

Market Cap

$5.18M

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

99801.76 (High)

Price

$3.35

Volume

1,700

Open

$3.35

Previous Close

$3.35

Daily Range

$3.35 - $3.35

52-Week Range

$2.41 - $3.35

PDRX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PD-Rx Pharmaceuticals

Industry

Healthcare Providers and Services

Sector

Health Care

CEO

Robert D. Holsey, PhD

Website

www.pdrx.com

Headquarters

Oklahoma City, OK 73127, US

PDRX Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

-3%

Net Income Margin

-1%

Return on Equity

0%

Return on Capital

-5%

Return on Assets

-2%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.18M

Shares Outstanding

1.54M

Volume

1.70K

Avg. Volume

50.794

Financials (TTM)

Gross Profit

$0.00

Operating Income

$477.42K

EBITDA

$477.42K

Operating Cash Flow

$765.03K

Capital Expenditure

$2.44K

Free Cash Flow

$762.59K

Cash & ST Invst.

$6.17M

Total Debt

$0.00

PD-Rx Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

$5.18M

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Net Cash

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CPIVFCaptiva Verde Wellness Corp.
$0.01-57.14%
SEHCFSweet Earth Holdings Corporation
$0.50+0.00%
RMSLREMSleep Holdings, Inc.
$0.00+2.22%
FZMDFuse Medical, Inc.
$0.03+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$13.30+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.07+0.05%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.70+0.01%
SOFISoFi Technologies
$16.43+0.02%

Questions About PDRX

What is the current price of PD-Rx Pharmaceuticals?

PD-Rx Pharmaceuticals is trading at $3.35 per share.

What is the 52-week range for PD-Rx Pharmaceuticals?

Over the past 52 weeks, PD-Rx Pharmaceuticals has traded between $2.41 and $3.35.

How much debt does PD-Rx Pharmaceuticals have?

As of the most recent reporting period, PD-Rx Pharmaceuticals reported total debt of N/A.

How much cash does PD-Rx Pharmaceuticals have on hand?

PD-Rx Pharmaceuticals reported $6.17M in cash and cash equivalents in its most recent financial results.

What is PD-Rx Pharmaceuticals’s dividend yield?

PD-Rx Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services